Loading
A phase 1 trial of ELVN-002 run by Enliven Therapeutics, active and no longer recruiting.
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer is a phase 1 interventional study registered as NCT05650879 by Enliven Therapeutics, with 198 participants planned, started 2023-03-20. Conditions recorded: HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation and HER2 Amplification. Interventions recorded: ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki and Trastuzumab emtansine.
Shares ELVN-002, Enliven Therapeutics, HER2-positive breast cancer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Enliven Therapeutics and the tag pipeline.
Shares Enliven Therapeutics and the tag pipeline.
Shares Enliven Therapeutics and the tag pipeline.
Shares HER2-positive breast cancer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares HER2-mutant non-small-cell lung cancer and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/